°³¿ä
´ã³¶¾Ï Ä¡·áÁ¦ ½ÃÀåÀº 2023-2028³â 1¾ï 4,147¸¸ ´Þ·¯·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 6.63%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ º¸°í¼´Â ´ã³¶¾Ï Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇÑ Àü¹ÝÀûÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ ´ë»óÀ¸·Î ÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
ÇöÀç ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ÃËÁø¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. °³¹ßµµ»ó±¹ ½ÃÀåÀÇ ³ôÀº ´ã³¶¾Ï ¹ßº´·ü, ´ã³¶¾ÏÀÇ À§Çè ¿äÀÎ, ´ã³¶¾Ï Ä¡·á¸¦ À§ÇÑ ¸é¿ª¿ä¹ýÀÇ µîÀå µîÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ |
±âÁØ ¿¬µµ |
2023 |
Á¾·á ¿¬µµ |
2028 |
¿¹Ãø ±â°£ |
2024-2028 |
¼ºÀå ¸ð¸àÅÒ |
°¡¼Ó |
Àü³â ´ëºñ 2024³â |
5.42% |
CAGR |
6.63% |
ÁõºÐ ±Ý¾× |
1¾ï 4,147¸¸ ´Þ·¯ |
ÀÌ º¸°í¼´Â ÇâÈÄ ¸î ³â°£ ´ã³¶¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î ´ã³¶¾Ï¿¡ ´ëÇÑ °·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎÀ» ²Å¾Ò½À´Ï´Ù. ¶ÇÇÑ, ¸é¿ª¿ä¹ý ¹× Â÷¼¼´ë ¿°±â¼¿ ºÐ¼®(NGS) ±â¹Ý °Ë»çÀÇ µµÀÔÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ö¿ä¸¦ °ßÀÎÇÏ´Â ¿äÀÎÀ¸·Î ²ÅÇû½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå »óȲ
Á¦3Àå ½ÃÀå ±Ô¸ð
- ½ÃÀå Á¤ÀÇ
- ½ÃÀå ºÎ¹® ºÐ¼®
- ½ÃÀå ±Ô¸ð 2023
- ½ÃÀå Àü¸Á 2023-2028
Á¦4Àå ½ÃÀå ±Ô¸ð ½ÇÀû
- ´ã³¶¾Ï Ä¡·áÁ¦ ¼¼°è ½ÃÀå 2018-2022
- À¯Çü ºÎ¹® ºÐ¼® 2018-2022
- ¿ëµµº° ºÎ¹® ºÐ¼® 2018-2022
- Áö¿ªº° ºÎ¹® ºÐ¼® 2018-2022
- ±¹°¡º° ºÎ¹® ºÐ¼® 2018-2022
Á¦5Àå Five Forces ºÐ¼®
- Five Forces ¿ä¾à
- ±¸¸ÅÀÚÀÇ ±³¼··Â
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀïÀÇ À§Çù
- ½ÃÀå »óȲ
Á¦6Àå ½ÃÀå ¼¼ºÐÈ : À¯Çüº°
- ½ÃÀå ºÎ¹®
- ºñ±³ : À¯Çüº°
- º´¿ë¿ä¹ý : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- ´Üµ¶¿ä¹ý : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- ½ÃÀå ±âȸ : À¯Çüº°
Á¦7Àå ½ÃÀå ¼¼ºÐÈ : ¿ëµµº°
- ½ÃÀå ºÎ¹®
- ºñ±³ : ¿ëµµº°
- º´¿ø : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- Çмú ¼¾ÅÍ¿Í ÀÇ·á ¼¾ÅÍ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- ±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- ½ÃÀå ±âȸ : ¿ëµµº°
Á¦8Àå °í°´ »óȲ
Á¦9Àå Áö¿ªº° »óȲ
- Áö¿ªº° ¼¼ºÐÈ
- Áö¿ªº° ºñ±³
- ºÏ¹Ì : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- À¯·´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- ¾Æ½Ã¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- ¼¼°è ±âŸ Áö¿ª : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- ¹Ì±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- ¿µ±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- Áß±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- ij³ª´Ù : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- Àεµ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028
- ½ÃÀå ±âȸ : Áö¿ªº°
Á¦10Àå ÃËÁø¿äÀÎ, °úÁ¦ ¹× µ¿Çâ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀå °úÁ¦
- ¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
- ½ÃÀå µ¿Çâ
Á¦11Àå º¥´õ »óȲ
- °³¿ä
- º¥´õ »óȲ
- È¥¶õ »óȲ
- ¾÷°è ¸®½ºÅ©
Á¦12Àå º¥´õ ºÐ¼®
- ´ë»ó º¥´õ
- º¥´õÀÇ ½ÃÀå Æ÷Áö¼Å´×
- AbbVie Inc.
- B.Braun SE
- Boston Scientific Corp.
- Bristol Myers Squibb Co.
- Conmed Corp.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- Medtronic Plc
- Novartis AG
- Olympus Corp.
- Pfizer Inc.
- Sanofi SA
- Smith and Nephew plc
- Sun Pharmaceutical Industries Ltd.
Á¦13Àå ºÎ·Ï
ksm
Abstract
The gallbladder cancer therapeutics market is forecasted to grow by USD 141.47 mn during 2023-2028, accelerating at a CAGR of 6.63% during the forecast period. The report on the gallbladder cancer therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, challenges, and vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the strong incidence of gallbladder cancer in developing countries, risk factors of gallbladder cancer, and the advent of immunotherapy for the treatment of gallbladder cancer.
Market Scope |
Base Year | 2023 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 5.42% |
CAGR | 6.63% |
Incremental Value | $141.47mn |
Technavio's gallbladder cancer therapeutics market is segmented as below:
By Type
- Combination therapy
- Monotherapy
By Application
- Hospitals
- Academic and medical centers
- Others
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the strong pipeline for gallbladder cancer as one of the prime reasons driving the gallbladder cancer therapeutics market growth during the next few years. Also, the rising adoption of immunotherapy and next-generation sequencing (NGS) based testing will lead to sizable demand in the market.
The report on the gallbladder cancer therapeutics market covers the following areas:
- Gallbladder cancer therapeutics market sizing
- Gallbladder cancer therapeutics market forecast
- Gallbladder cancer therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gallbladder cancer therapeutics market vendors that include AbbVie Inc., AstraZeneca Plc, B.Braun SE, Boston Scientific Corp., Bristol Myers Squibb Co., Conmed Corp., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Medtronic Plc, Merck KGaA, Novartis AG, Olympus Corp., Pfizer Inc., Sanofi SA, Smith and Nephew plc, and Sun Pharmaceutical Industries Ltd.. Also, the gallbladder cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape and an analysis of the key vendors.
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary - Chart on Market Overview
- Exhibit 02: Executive Summary - Data Table on Market Overview
- Exhibit 03: Executive Summary - Chart on Global Market Characteristics
- Exhibit 04: Executive Summary - Chart on Market by Geography
- Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary - Chart on Market Segmentation by Application
- Exhibit 07: Executive Summary - Chart on Incremental Growth
- Exhibit 08: Executive Summary - Data Table on Incremental Growth
- Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2023
- 3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
- 4.1 Global gallbladder cancer therapeutics market 2018 - 2022
- Exhibit 18: Historic Market Size - Data Table on global gallbladder cancer therapeutics market 2018 - 2022 ($ million)
- 4.2 Type Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
- 4.3 Application Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size - Application Segment 2018 - 2022 ($ million)
- 4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
- 4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Type
- 6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
- 6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type
- 6.3 Combination therapy - Market size and forecast 2023-2028
- Exhibit 34: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 35: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 36: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)
- 6.4 Monotherapy - Market size and forecast 2023-2028
- Exhibit 38: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 39: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
- Exhibit 40: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)
- 6.5 Market opportunity by Type
- Exhibit 42: Market opportunity by Type ($ million)
- Exhibit 43: Data Table on Market opportunity by Type ($ million)
7 Market Segmentation by Application
- 7.1 Market segments
- Exhibit 44: Chart on Application - Market share 2023-2028 (%)
- Exhibit 45: Data Table on Application - Market share 2023-2028 (%)
- 7.2 Comparison by Application
- Exhibit 46: Chart on Comparison by Application
- Exhibit 47: Data Table on Comparison by Application
- 7.3 Hospitals - Market size and forecast 2023-2028
- Exhibit 48: Chart on Hospitals - Market size and forecast 2023-2028 ($ million)
- Exhibit 49: Data Table on Hospitals - Market size and forecast 2023-2028 ($ million)
- Exhibit 50: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
- Exhibit 51: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
- 7.4 Academic and medical centers - Market size and forecast 2023-2028
- Exhibit 52: Chart on Academic and medical centers - Market size and forecast 2023-2028 ($ million)
- Exhibit 53: Data Table on Academic and medical centers - Market size and forecast 2023-2028 ($ million)
- Exhibit 54: Chart on Academic and medical centers - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Academic and medical centers - Year-over-year growth 2023-2028 (%)
- 7.5 Others - Market size and forecast 2023-2028
- Exhibit 56: Chart on Others - Market size and forecast 2023-2028 ($ million)
- Exhibit 57: Data Table on Others - Market size and forecast 2023-2028 ($ million)
- Exhibit 58: Chart on Others - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Others - Year-over-year growth 2023-2028 (%)
- 7.6 Market opportunity by Application
- Exhibit 60: Market opportunity by Application ($ million)
- Exhibit 61: Data Table on Market opportunity by Application ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2023-2028 (%)
- Exhibit 64: Data Table on Market share by geography 2023-2028 (%)
- 9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2023-2028
- Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
- 9.4 Europe - Market size and forecast 2023-2028
- Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
- 9.5 Asia - Market size and forecast 2023-2028
- Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- 9.7 US - Market size and forecast 2023-2028
- Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
- 9.8 UK - Market size and forecast 2023-2028
- Exhibit 87: Chart on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 88: Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 89: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on UK - Year-over-year growth 2023-2028 (%)
- 9.9 China - Market size and forecast 2023-2028
- Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
- 9.10 Canada - Market size and forecast 2023-2028
- Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
- 9.11 India - Market size and forecast 2023-2028
- Exhibit 99: Chart on India - Market size and forecast 2023-2028 ($ million)
- Exhibit 100: Data Table on India - Market size and forecast 2023-2028 ($ million)
- Exhibit 101: Chart on India - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on India - Year-over-year growth 2023-2028 (%)
- 9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ million)
- Exhibit 104: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2023 and 2028
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 108: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 109: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification
- 12.3 AbbVie Inc.
- Exhibit 111: AbbVie Inc. - Overview
- Exhibit 112: AbbVie Inc. - Product / Service
- Exhibit 113: AbbVie Inc. - Key news
- Exhibit 114: AbbVie Inc. - Key offerings
- 12.4 B.Braun SE
- Exhibit 115: B.Braun SE - Overview
- Exhibit 116: B.Braun SE - Business segments
- Exhibit 117: B.Braun SE - Key news
- Exhibit 118: B.Braun SE - Key offerings
- Exhibit 119: B.Braun SE - Segment focus
- 12.5 Boston Scientific Corp.
- Exhibit 120: Boston Scientific Corp. - Overview
- Exhibit 121: Boston Scientific Corp. - Business segments
- Exhibit 122: Boston Scientific Corp. - Key news
- Exhibit 123: Boston Scientific Corp. - Key offerings
- Exhibit 124: Boston Scientific Corp. - Segment focus
- 12.6 Bristol Myers Squibb Co.
- Exhibit 125: Bristol Myers Squibb Co. - Overview
- Exhibit 126: Bristol Myers Squibb Co. - Product / Service
- Exhibit 127: Bristol Myers Squibb Co. - Key news
- Exhibit 128: Bristol Myers Squibb Co. - Key offerings
- 12.7 Conmed Corp.
- Exhibit 129: Conmed Corp. - Overview
- Exhibit 130: Conmed Corp. - Business segments
- Exhibit 131: Conmed Corp. - Key offerings
- Exhibit 132: Conmed Corp. - Segment focus
- 12.8 Eli Lilly and Co.
- Exhibit 133: Eli Lilly and Co. - Overview
- Exhibit 134: Eli Lilly and Co. - Product / Service
- Exhibit 135: Eli Lilly and Co. - Key news
- Exhibit 136: Eli Lilly and Co. - Key offerings
- 12.9 F. Hoffmann La Roche Ltd.
- Exhibit 137: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 138: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 139: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 140: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 141: F. Hoffmann La Roche Ltd. - Segment focus
- 12.10 Gilead Sciences Inc.
- Exhibit 142: Gilead Sciences Inc. - Overview
- Exhibit 143: Gilead Sciences Inc. - Product / Service
- Exhibit 144: Gilead Sciences Inc. - Key news
- Exhibit 145: Gilead Sciences Inc. - Key offerings
- 12.11 Medtronic Plc
- Exhibit 146: Medtronic Plc - Overview
- Exhibit 147: Medtronic Plc - Business segments
- Exhibit 148: Medtronic Plc - Key news
- Exhibit 149: Medtronic Plc - Key offerings
- Exhibit 150: Medtronic Plc - Segment focus
- 12.12 Novartis AG
- Exhibit 151: Novartis AG - Overview
- Exhibit 152: Novartis AG - Business segments
- Exhibit 153: Novartis AG - Key offerings
- Exhibit 154: Novartis AG - Segment focus
- 12.13 Olympus Corp.
- Exhibit 155: Olympus Corp. - Overview
- Exhibit 156: Olympus Corp. - Business segments
- Exhibit 157: Olympus Corp. - Key news
- Exhibit 158: Olympus Corp. - Key offerings
- Exhibit 159: Olympus Corp. - Segment focus
- 12.14 Pfizer Inc.
- Exhibit 160: Pfizer Inc. - Overview
- Exhibit 161: Pfizer Inc. - Product / Service
- Exhibit 162: Pfizer Inc. - Key news
- Exhibit 163: Pfizer Inc. - Key offerings
- 12.15 Sanofi SA
- Exhibit 164: Sanofi SA - Overview
- Exhibit 165: Sanofi SA - Business segments
- Exhibit 166: Sanofi SA - Key news
- Exhibit 167: Sanofi SA - Key offerings
- Exhibit 168: Sanofi SA - Segment focus
- 12.16 Smith and Nephew plc
- Exhibit 169: Smith and Nephew plc - Overview
- Exhibit 170: Smith and Nephew plc - Business segments
- Exhibit 171: Smith and Nephew plc - Key news
- Exhibit 172: Smith and Nephew plc - Key offerings
- Exhibit 173: Smith and Nephew plc - Segment focus
- 12.17 Sun Pharmaceutical Industries Ltd.
- Exhibit 174: Sun Pharmaceutical Industries Ltd. - Overview
- Exhibit 175: Sun Pharmaceutical Industries Ltd. - Product / Service
- Exhibit 176: Sun Pharmaceutical Industries Ltd. - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 177: Inclusions checklist
- Exhibit 178: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 179: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 180: Research methodology
- Exhibit 181: Validation techniques employed for market sizing
- Exhibit 182: Information sources
- 13.5 List of abbreviations
- Exhibit 183: List of abbreviations